FDA Approved Indications for this Orphan Drug:
Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus.FDA Marketing Approval issued as of:
06/11/1996
Orphan Drug exclusivity ends on:
06/11/2003
06/11/2003
Company Making and Marketing this drug:
Amedra Pharmaceuticals LLC
Amedra Pharmaceuticals LLC
FDA Designation Date:
1/17/96
FDA Drug Designation:
Treatment of hydatid disease (cystic echinococcosis due to E. granulosus larvae or alveolar echinococcosis due to E. multilocularis larvae).
